Key Points
- Director Srinivas Akkaraju bought a total of 643,260 shares in multiple trades from Nov 13–20 (including 125,743 shares on Nov 20 at $7.20), investing roughly $3.9M and increasing his stake by 24.3% to holdings valued at about $4.63M.
- Alumis reported an EPS loss of $1.06 for the quarter (vs. -$0.92 expected) and revenue of $2.07M (below $3.14M est.); the stock trades near $7.30 and carries a consensus “Moderate Buy” with an average analyst target of $19.20 amid mixed ratings.
Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Srinivas Akkaraju bought 125,743 shares of the business's stock in a transaction dated Thursday, November 20th. The shares were acquired at an average cost of $7.20 per share, with a total value of $905,349.60. Following the completion of the purchase, the director owned 643,260 shares in the company, valued at approximately $4,631,472. This represents a 24.30% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Srinivas Akkaraju also recently made the following trade(s):
- On Wednesday, November 19th, Srinivas Akkaraju purchased 137,772 shares of Alumis stock. The stock was acquired at an average price of $6.56 per share, for a total transaction of $903,784.32.
- On Tuesday, November 18th, Srinivas Akkaraju acquired 102,652 shares of Alumis stock. The shares were acquired at an average cost of $6.05 per share, for a total transaction of $621,044.60.
- On Monday, November 17th, Srinivas Akkaraju bought 914 shares of Alumis stock. The stock was acquired at an average cost of $5.51 per share, with a total value of $5,036.14.
- On Thursday, November 13th, Srinivas Akkaraju bought 276,179 shares of Alumis stock. The shares were bought at an average price of $5.25 per share, for a total transaction of $1,449,939.75.
Alumis Stock Performance
ALMS stock opened at $7.30 on Tuesday. The company's 50-day moving average price is $4.77 and its 200 day moving average price is $4.28. Alumis Inc. has a 52 week low of $2.76 and a 52 week high of $10.49. The company has a market cap of $762.07 million, a P/E ratio of -1.80 and a beta of -1.33.
Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to the consensus estimate of $3.14 million. On average, equities research analysts expect that Alumis Inc. will post -8.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
ALMS has been the topic of several research reports. Morgan Stanley lowered their target price on Alumis from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, August 15th. HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of Alumis in a report on Thursday, August 14th. Wall Street Zen cut shares of Alumis from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alumis in a research report on Thursday, November 13th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Alumis has a consensus rating of "Moderate Buy" and an average target price of $19.20.
Get Our Latest Stock Report on Alumis
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in shares of Alumis by 37.0% during the 1st quarter. Bank of New York Mellon Corp now owns 42,403 shares of the company's stock worth $260,000 after purchasing an additional 11,453 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Alumis by 12.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 127,854 shares of the company's stock valued at $785,000 after buying an additional 14,453 shares during the last quarter. Invesco Ltd. purchased a new position in shares of Alumis during the first quarter valued at approximately $164,000. Nuveen LLC purchased a new position in shares of Alumis during the first quarter valued at approximately $105,000. Finally, Corebridge Financial Inc. boosted its position in Alumis by 53.0% during the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company's stock worth $65,000 after acquiring an additional 3,693 shares during the last quarter.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
